Welcome to CHARTER

Welcome to CHARTER as a Resource

The CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) study was first funded in September 2002 in response to NIMH RFA 00-AI-0005 to explore the changing presentation of HIV neurological complications in the context of emerging antiviral treatments such as highly active antiretroviral therapy (HAART). Current public funding includes grants from the National Institute of Health (NIH), the National Institute of Mental Health (NIMH) and the National Institute of Neurological Disorders and Stroke (NINDS) via the CHARTER Extension (NIMH/NINDS Award Number HHS-N-271-2010-00036C) and CHARTER As A Resource (NIH/NIMH/NINDS Award Number HHSN271201000030C).

CHARTER’s study aims are to determine how central and peripheral nervous system complications of HIV are affected by different histories and regimens of antiretroviral therapy (ART). Participants receive comprehensive neuromedical, neurocognitive, and laboratory examinations, with a subset undergoing host/viral genetic characterization and neuroimaging. In order to have a broad representation of participant characteristics, CHARTER is conducted at six performance sites nationally whose activities are coordinated by UCSD, the principal grantee institution, which includes several technical, scientific, and administrative cores to guide the work.




David Moore Featured in UC Social Media Campaign Video "PrEParing for HIV"

UC researchers, including Dr. David Moore of the HIV Neurobehavioral Research Program, are conducting a 4-year study on pre-exposure prophylaxis (PrEP).  PrEP is a prevention strategy for people at high risk for contracting HIV.


POZ Magazine Highlights the Research of Several CHARTER Investigators

In the May 1, 2013, edition of POZ Benjamin Ryan presents CHARTER research on aging and HIV in his article "Braving Cognitive Decline: Can People With HIV Fight Back?".  Drs. Simpson, MacArthur and Letendre weigh in on several issues associated with HIV and aging including mild cognitive impairment and accelerated/increased rates of disorders such as osteoporosis, cardiovascular disease and B12 deficiency.  Co-morbidities such as neurosyphilis and Hepatitis C are also discussed.  In general patients with HIV are not experiencing the extreme dementia and the early mortality seen in the past, but living longer with HIV brings other issues that can diminish quality of life.

To read the article click here.


CHARTER Investigators Present at CROI 2014

The 21st Annual Conference on Retroviruses and Opportunistic Infections (CROI) occurs from March 3 to March 6, 2014 in Boston, Massachusetts.

CROI brings together top basic, translational, and clinical researchers from around the world to share the latest studies, important developments, and best research methods in the ongoing battle against HIV/AIDS and related infectious diseases.


CHARTER Investigators at the North European Workshop on HIV infection in the CNS (HANSA 2013)

Presentation: HAND is Common and Important in Patients on ART, Igor Grant, MD (PDF)

Drs. Igor Grant and Scott Letendre presented at the third North European Workshop on HIV–infection in the central nervous system (HANSA 2013) that took place in Berlin, Germany, 26-27 April 2013.  The aim of HANSA 2013 is to assemble clinicians and researchers together to advance knowledge of ongoing HIV central nervous system (CNS) research. The conference covered basic issues and controversies.

  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  Next 
  •  End 
  • »

Page 1 of 2

Sponsored by NIH/NIMH/NINDS HHSN271201000036C & HHSN271201000030C

Copyright ©2010 CNS HIV ANTI-RETROVIRAL THERAPY EFFECTS RESEARCH | University of California, San Diego | contact the webmaster